Latest news with #CPBLF
Yahoo
4 days ago
- Business
- Yahoo
ALS Ltd (CPBLF) (FY 2025) Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...
Revenue Growth: 16% increase to $3 billion. Underlying EBIT Growth: 4.7% increase, 7.7% on a constant currency basis. EBIT Margin: 19.1% excluding recent acquisitions; overall margin declined to 17.2%. Minerals Margin: Maintained at approximately 31%. Life Sciences Organic Growth: 9.8% in Environmental sector. Cash Conversion: 95% of underlying EBITDA. Net Profit After Tax (NPAT): Declined 1.4% to $312.1 million; increased 2.8% on a constant currency basis. Dividend: Final dividend of $19.7 per share, 60% payout ratio. Commodities Revenue Growth: 0.2% increase; 2.5% on a constant currency basis. Industrial Materials Organic Growth: 11.3% with margin improvements. Life Sciences Revenue Growth: 27.4% total growth; 6.6% organic growth. Leverage: 2.3 times, at the upper end of the target range. Capital Expenditure: $165 million, 5.5% of revenue. Interest Expense: Approximately $82 million in FY25. Debt Maturity: Weighted average debt maturity of 4.7 years. Warning! GuruFocus has detected 10 Warning Sign with CPBLF. Release Date: May 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. ALS Ltd (CPBLF) reported strong revenue growth of 16% to $3 billion for fiscal year '25, demonstrating the strength of its diversified and resilient operating model. The company achieved a robust EBIT margin of 19.1% excluding recent acquisitions, aligning with its strategic plan objectives. Life Sciences division delivered industry-leading organic growth of 9.8% in Environmental, benefiting from increased testing demand for PFAS. ALS Ltd (CPBLF) maintained a strong cash conversion rate of 95% of underlying EBITDA, supporting its capital framework and growth journey. The company declared a final dividend of $19.7 per share, reflecting a 60% payout ratio, supported by solid performance and liquidity. The underlying EBIT margin declined to 17.2% due to dilution from recent acquisitions and cyclical pricing pressures in Minerals. Return on capital employed decreased to 18.9%, impacted by recent acquisitions. Underlying net profit after tax declined by 1.4% to $312.1 million, although it increased by 2.8% on a constant currency basis. The company's leverage ratio was at the upper end of its target range at 2.3 times, reflecting investment and integration activities. ALS Ltd (CPBLF) faces a $5 million to $10 million EBIT risk in fiscal year '26 due to changes in Mexican pharmaceutical testing regulations. Q: Are you expecting recovery from other regions in the minerals sector, and what is your outlook for 2026? A: Malcolm Deane, CEO: Recovery is coming from South America, Australia, and Central Asia. North America shows mixed results, with Eastern Canada performing better than Western Canada. The recovery is driven by majors and mid-tiers, with a slight increase in gold activities. It's too early to determine the full impact from juniors. Q: What are the drivers of the above-average growth in the Environmental sector? A: Malcolm Deane, CEO: Growth is driven by pricing discipline, market share gains due to reliable service, and enforcement of existing regulations. The Environmental business has experienced consistent margin improvement and top-line growth. Q: Can you provide more details on minerals testing volumes and trends in the fourth quarter? A: Malcolm Deane, CEO: Improved momentum began at the start of Q4, with mining activities resuming earlier than usual. Sample volumes have remained steady, allowing for inventory rebuilding and a change in pricing momentum. We raised prices by 4-5% at the beginning of the calendar year. Q: How should we think about the deployment of surplus funds from acquisitions? A: Malcolm Deane, CEO: Expect no major deployments in the next six months as we focus on completing current integrations. We are looking at opportunities in minerals, particularly in non-exploration areas, and expanding our Environmental business. These opportunities may take 12 months to realize. Q: What is the rationale behind moving the head office to Madrid? A: Malcolm Deane, CEO: The move consolidates the executive team in Europe, improving decision-making agility. Europe is a focus area with 40% of our workforce, and Madrid offers cost advantages. The move aligns with recent hires and strategic focus on European markets. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Business Insider
29-04-2025
- Business
- Business Insider
UBS Reaffirms Their Buy Rating on ALS (CPBLF)
UBS analyst Nathan Reilly maintained a Buy rating on ALS (CPBLF – Research Report) today and set a price target of A$18.70. The company's shares closed last Thursday at $9.53. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Reilly is ranked #1423 out of 9371 analysts. ALS has an analyst consensus of Strong Buy, with a price target consensus of $11.01. CPBLF market cap is currently $4.87B and has a P/E ratio of 929.09.
